Ingevity Corporation (NGVT) Guidance & Earnings Results

On 2026-07-29 Ingevity Corporation raised guidance: "FY2026 net sales $1.05-1.15B; adjusted EBITDA $380-400M; diluted adjusted EPS $5.00-5.45; free cash flow $220-245M…" — from its own filing, as read by EquiReason.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

NGVTIngevity CorporationFollow NGVT — free

Specialty Chemicals · Basic Materials

—

Price chart with a free account

Market cap: 2.4B
P/E TTM: 46.4
Dividend yield: —
52-week: —
Next earnings: 4 Nov, in 11 days

What management guided

each earnings 8-K · figures checked against the filing text

Release	Direction	What they said
29 Jul 26	Raised	FY2026 net sales $1.05-1.15B; adjusted EBITDA $380-400M; diluted adjusted EPS $5.00-5.45; free cash flow $220-245M ex-litigation · full year
6 May 26	Reaffirmed	FY2026 net sales $1.05B-$1.15B, adjusted EBITDA $370M-$395M, adjusted EPS $4.70-$5.20, FCF $215M-$245M (excl. $113.2M litigation payment) · full year
5 Nov 25	Lowered	Total net sales $1.25B-$1.35B; Total adjusted EBITDA $390M-$405M · full year
4 Aug 25	Raised	FY25 adjusted EBITDA guidance raised to $390M-$415M from $390M-$415M (low-end raised); FY25 sales guidance maintained at $1.25B-$1.40B · full year

Ingevity Corporation — questions

What guidance did Ingevity Corporation give?: On 2026-07-29: "FY2026 net sales $1.05-1.15B; adjusted EBITDA $380-400M; diluted adjusted EPS $5.00-5.45; free cash flow $220-245M ex-litigation"
When does Ingevity Corporation report earnings?: Ingevity Corporation's next earnings report is expected on 2026-11-04.

Every figure on this page comes from Ingevity Corporation's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.

Important information. Figures on this page are taken from filings submitted to the U.S. Securities and Exchange Commission (SEC) and processed automatically by EquiReason. They may contain errors, omissions or delays, and EquiReason makes no representation or warranty as to their accuracy, completeness or timeliness. Always verify figures against the original filing on SEC EDGAR before relying on them.

This page is provided for general information and educational purposes only. It does not constitute investment, financial, legal or tax advice, and it is not a recommendation or an offer to buy, sell or hold any security. It does not take into account your objectives, financial situation or needs. Past performance does not guarantee future results; any reliance on this information is at your own risk. See our Disclaimer and Risk Disclosure.